Fluoroethyltyrosine for Brain Tumor

Overseen By Louise Magat

Age: Any Age

Sex: Any

Trial Phase: Academic

Sponsor: Thomas Hope

Disqualifiers: Incompatibility with PET/CT/MRI, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

199 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new method to detect brain tumors using a compound called Fluoroethyltyrosine (FET), which highlights cancerous cells. The researchers aim to determine if FET can identify returning tumors or assess tumor severity, especially when regular imaging is unclear. Suitable participants include individuals with suspected or previously treated brain tumors, particularly if there is concern about recurrence or worsening. The trial consists of two groups: one for those concerned about tumor recurrence after treatment, and another for those planning to undergo a biopsy or surgery before starting standard treatment. As a Phase 2 trial, this research measures how well FET works in an initial, smaller group, offering participants a chance to contribute to significant advancements in brain tumor detection.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

What prior data suggests that Fluoroethyltyrosine is safe for detecting brain tumors?

Studies have shown that Fluoroethyltyrosine (FET) is generally safe for detecting brain tumors. Research indicates that FET accumulates in cancer cells, aiding doctors in locating and evaluating brain tumors. No major reports of serious side effects have emerged, suggesting that FET imaging is safe for individuals with brain tumors. However, as with any medical procedure, discussing personal risks with a doctor is important. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about using fluoroethyltyrosine for evaluating intracranial neoplasms because it offers a new way to visualize brain tumors. Unlike standard imaging techniques like MRI or CT scans, which sometimes struggle to differentiate between tumor tissue and other changes in the brain, fluoroethyltyrosine is a radiolabeled amino acid that can more precisely target tumor cells. This specificity could improve the accuracy of diagnosing tumor recurrence or progression, potentially leading to better treatment decisions and outcomes for patients with brain tumors.

What evidence suggests that Fluoroethyltyrosine is effective for detecting brain tumors?

This trial will evaluate fluoroethyltyrosine (FET) in two different participant groups. Research has shown that FET effectively identifies brain tumors. Studies have found that FET PET scans outperform the more common FDG PET scans for this purpose. FET helps doctors see tumors more clearly and understand their growth patterns. By accumulating in cancer cells, FET proves useful for detecting recurrent tumors and assessing tumor severity, aiding in treatment planning. While more information is still being gathered, these findings suggest FET holds promise for evaluating brain tumors. ^{2 6 7 8 9}

Who Is on the Research Team?

Javier Villanueva-Meyer, MD

Principal Investigator

University of California, San Francisco

Are You a Good Fit for This Trial?

Inclusion Criteria

I've had initial treatment and my MRI suggests my cancer might be back.

My cancer has returned and spread to other parts.

My brain tumor is a high-grade (Grade 3 or 4) glioma that has come back.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

PET Scan

Participants receive a single FET PET scan lasting about 40 minutes in an outpatient setting after an injection with FET. Adult participants may undergo up to two repeat FET PET scans.

1 day

1-3 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after the PET scan. Adverse events will be recorded.

Up to 3 years

What Are the Treatments Tested in This Trial?

Interventions

• Fluoroethyltyrosine

How Is the Trial Designed?

Group I: Population 2: Participants with suspected glial neoplasms Experimental Treatment 2 Interventions

Participants with suspected glial neoplasms (Grade 2 - 4) planning to undergo biopsy or surgery prior to non-investigational, standard-of-care, primary treatment (radiation therapy and/or surgery)

Group II: Population 1: Participants with intracranial neoplasms Experimental Treatment 2 Interventions

Participants with intracranial neoplasms (glial or metastatic disease) with concern for recurrence or progression on conventional imaging.

Who Is Running the Clinical Trial?

Thomas Hope

Lead Sponsor

Trials

11

Recruited

1,800+

Citations

1. clinicaltrials.gov clinicaltrials.gov/study/NCT04044937

Study Details | NCT04044937 | Fluoroethyltyrosine for ... This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that ...

2. jnm.snmjournals.org jnm.snmjournals.org/content/53/2/207

Performance of 18 F-Fluoro-Ethyl-Tyrosine ( 18 F-FET) PET for ... Even with treatment, median survival rates are in the range of 15–18 mo for glioblastoma and 2–3 y for anaplastic astrocytoma. Although ...

3. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC4767236/

Performance of 18F-FET versus 18F-FDG-PET for the ... For brain tumor diagnosis, FET-PET performed much better than FDG and should be preferred when assessing a new isolated brain tumor.

4. sciencedirect.com sciencedirect.com/science/article/abs/pii/S0969805120300299

Current trends in the use of O-(2-[ 18 F]fluoroethyl)-L- ... This review summarizes the basic knowledge on [18F]FET and its contribution to the care of patients with brain tumors. In particular, recent studies about ...

5. clinicaltrials.ucsf.edu clinicaltrials.ucsf.edu/trial/NCT06474533

Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors.

6. clinicaltrials.gov clinicaltrials.gov/study/NCT04044937

Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that ...

7. clinicaltrials.ucsf.edu clinicaltrials.ucsf.edu/brain-tumor

UCSF Brain Tumor Clinical Trials — San Francisco Bay Area This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant ...

8. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC7966252/

Prediction of Glioma Recurrence Using Dynamic 18F ... F-fluoroethyltyrosine-PET can predict recurrence in patients with glioma, with dynamic analysis showing advantages over static imaging, especially in the low- ...

9. cancer.gov cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-04996

Fluoroethyltyrosine for the Evaluation of Intracranial ... This study is being done to test how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) (FET) with positron emission tomography (PET) works in the imaging ...